{
    "id": 5183,
    "date": "2026-09-24T11:55:00",
    "date_gmt": "2026-09-24T09:55:00",
    "guid": {
        "rendered": "https:\/\/www.phinc-group.com\/?p=5183"
    },
    "modified": "2026-09-24T12:47:04",
    "modified_gmt": "2026-09-24T10:47:04",
    "slug": "reduction-du-risque-de-toxicite-cardiaque",
    "status": "publish",
    "type": "post",
    "link": "https:\/\/www.phinc-group.com\/fr\/reduction-du-risque-de-toxicite-cardiaque\/",
    "title": {
        "rendered": "R\u00e9duction du risque de toxicit\u00e9 cardiaque : L’\u00e9volution de l’\u00e9valuation de l’intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments"
    },
    "content": {
        "rendered": "<div data-elementor-type=\"wp-post\" data-elementor-id=\"5183\" class=\"elementor elementor-5183\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-778ab1f e-con-full e-flex e-con e-parent\" data-id=\"778ab1f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b77e2ec elementor-widget elementor-widget-html\" data-id=\"b77e2ec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>\r\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;1,300&family=Poppins:wght@200;300;600;700&display=swap');\r\n\r\n.midd-page{\r\n  --phinc-blue:#00005f;--phinc-pink:#d94b9f;\r\n  --ink:#0F172A;--muted:#475569;--line:#E6EAF2;--bg:#F7F9FC;--card:#FFFFFF;\r\n  --radius:18px;--shadow:0 10px 30px rgba(15,23,42,.08);\r\n  font-family:'Poppins',sans-serif;font-weight:300;color:var(--muted);background:var(--bg);\r\n  line-height:1.7;-webkit-font-smoothing:antialiased;\r\n}\r\n.midd-page *{box-sizing:border-box}\r\n.midd-wrap{max-width:1120px;margin:0 auto;padding:0 24px}\r\n.midd-narrow{max-width:820px}\r\n\r\n\/* HERO *\/\r\n.midd-hero{padding:88px 0 64px}\r\n.midd-hero-grid{display:grid;grid-template-columns:1.1fr .9fr;gap:56px;align-items:center}\r\n.midd-eyebrow{display:inline-flex;align-items:center;gap:10px;padding:8px 16px;border:1px solid var(--line);border-radius:999px;background:var(--card);font-size:12px;font-weight:600;letter-spacing:.14em;text-transform:uppercase;color:var(--phinc-blue)}\r\n.midd-eyebrow .dot{width:9px;height:9px;border-radius:50%;background:linear-gradient(135deg,var(--phinc-blue),var(--phinc-pink))}\r\n.midd-page h1{font-family:'Cormorant Garamond',serif;font-weight:300;font-size:58px;line-height:1.06;color:var(--phinc-blue);margin:22px 0 18px;letter-spacing:-.01em}\r\n.midd-page h1 em,.midd-page h2 em{font-style:normal;color:var(--phinc-pink)}\r\n.midd-sub{font-size:19px;font-weight:200;color:var(--muted);margin:0 0 26px;line-height:1.55}\r\n.midd-pills{display:flex;flex-wrap:wrap;gap:8px}\r\n.midd-pill{padding:6px 14px;border-radius:999px;background:var(--card);border:1px solid var(--line);font-size:12.5px;font-weight:300;color:var(--ink)}\r\n\r\n\/* IMAGE PLACEHOLDERS *\/\r\n.midd-img{position:relative;width:100%;aspect-ratio:16\/7;border-radius:var(--radius);border:1px solid var(--line);box-shadow:var(--shadow);background-color:#EEF1F8;background-size:cover;background-position:center;overflow:hidden}\r\n.midd-img.banner{aspect-ratio:21\/7}\r\n.midd-img.tall{aspect-ratio:4\/3}\r\n.midd-img--empty{border:2px dashed #C7CEDD;box-shadow:none;background-image:linear-gradient(135deg,rgba(0,0,95,.04),rgba(217,75,159,.06))}\r\n.midd-img--empty::after{content:attr(data-label);position:absolute;inset:0;display:flex;align-items:center;justify-content:center;text-align:center;padding:16px;font-size:13px;font-weight:600;letter-spacing:.08em;text-transform:uppercase;color:#94A3B8}\r\n\r\n\/* SECTIONS *\/\r\n.midd-section{padding:32px 0}\r\n.midd-kicker{display:block;font-size:12px;font-weight:600;letter-spacing:.18em;text-transform:uppercase;color:var(--phinc-pink);margin-bottom:12px}\r\n.midd-page h2{font-family:'Cormorant Garamond',serif;font-weight:300;font-size:38px;line-height:1.15;color:var(--phinc-blue);margin:0 0 24px}\r\n.midd-page p{font-size:16px;font-weight:300;color:var(--muted);margin:0 0 18px}\r\n.midd-page strong{font-weight:600;color:var(--ink)}\r\n.midd-page a{color:var(--phinc-blue);text-decoration:underline;text-decoration-color:rgba(217,75,159,.5);word-break:break-word}\r\n.midd-divider{height:1px;background:var(--line);border:0;margin:0}\r\n.midd-space{height:32px}\r\n\r\n\/* PULL QUOTE *\/\r\n.midd-quote{position:relative;margin:32px 0;padding:36px 40px 32px 72px;border-radius:var(--radius);background:linear-gradient(135deg,rgba(0,0,95,.05),rgba(217,75,159,.08));overflow:hidden}\r\n.midd-quote::before{content:\"\\201C\";position:absolute;left:18px;top:-18px;font-family:'Cormorant Garamond',serif;font-size:140px;line-height:1;color:var(--phinc-pink);opacity:.25}\r\n.midd-quote p{font-family:'Cormorant Garamond',serif;font-style:italic;font-weight:300;font-size:22px;line-height:1.5;color:var(--phinc-blue);margin:0}\r\n\r\n\/* COMPARISON CARDS *\/\r\n.midd-compare{display:grid;grid-template-columns:1fr 1fr;gap:20px;margin:28px 0}\r\n.midd-compare-card{background:var(--card);border-radius:var(--radius);box-shadow:var(--shadow);padding:28px;border-left:4px solid var(--phinc-blue)}\r\n.midd-compare-card.pink{border-left-color:var(--phinc-pink)}\r\n.midd-compare-card p{font-size:15px;margin:0}\r\n\r\n\/* FEATURE CARDS *\/\r\n.midd-cards{display:grid;grid-template-columns:repeat(3,1fr);gap:20px;margin:28px 0}\r\n.midd-card{background:var(--card);border:1px solid var(--line);border-radius:var(--radius);box-shadow:var(--shadow);padding:28px}\r\n.midd-chip{width:44px;height:44px;border-radius:12px;display:flex;align-items:center;justify-content:center;background:linear-gradient(135deg,var(--phinc-blue),var(--phinc-pink));margin-bottom:18px}\r\n.midd-chip svg{width:22px;height:22px;stroke:#fff;fill:none;stroke-width:1.8;stroke-linecap:round;stroke-linejoin:round}\r\n.midd-card h3{font-family:'Poppins',sans-serif;font-weight:600;font-size:16.5px;line-height:1.4;color:var(--ink);margin:0 0 10px}\r\n.midd-card p{font-size:14px;margin:0}\r\n.midd-tags{display:flex;flex-wrap:wrap;gap:6px;margin-top:16px}\r\n.midd-tag{padding:4px 10px;border-radius:999px;background:var(--bg);border:1px solid var(--line);font-size:11.5px;color:var(--phinc-blue)}\r\n\r\n\/* REFERENCES *\/\r\n.midd-refs p{font-size:14px}\r\n\r\n\/* CTA *\/\r\n.midd-cta{position:relative;overflow:hidden;border-radius:24px;padding:64px 56px;background:linear-gradient(135deg,#00005f 0%,#3a1a78 55%,#d94b9f 100%);color:#fff;margin:14px 0 88px}\r\n.midd-cta::before{content:\"\";position:absolute;right:-120px;top:-120px;width:420px;height:420px;border-radius:50%;background:radial-gradient(circle,rgba(217,75,159,.55),rgba(217,75,159,0) 70%)}\r\n.midd-cta > *{position:relative}\r\n.midd-cta h2{font-size:42px;color:#fff;margin-bottom:14px}\r\n.midd-cta h2 em{color:#f9b8e4}\r\n.midd-cta p{color:rgba(255,255,255,.82);max-width:1120px}\r\n.midd-btns{display:flex;flex-wrap:wrap;gap:12px;margin-top:28px}\r\n.midd-btn{display:inline-block;padding:14px 26px;border-radius:12px;font-family:'Poppins',sans-serif;font-weight:600;font-size:14.5px;text-decoration:none !important;transition:transform .2s}\r\n.midd-btn:hover{transform:translateY(-2px)}\r\n.midd-btn.primary{background:var(--phinc-pink);color:#fff !important;box-shadow:0 10px 24px rgba(217,75,159,.4)}\r\n.midd-btn.ghost{border:1px solid rgba(255,255,255,.45);background:rgba(255,255,255,.08);color:#fff !important;backdrop-filter:blur(8px);-webkit-backdrop-filter:blur(8px)}\r\n\r\n@media (max-width:900px){\r\n  .midd-hero-grid{grid-template-columns:1fr;gap:36px}\r\n  .midd-cards{grid-template-columns:1fr}\r\n  .midd-compare{grid-template-columns:1fr}\r\n  .midd-page h1{font-size:42px}\r\n  .midd-page h2{font-size:32px}\r\n  .midd-cta{padding:44px 28px}\r\n  .midd-cta h2{font-size:34px}\r\n  .midd-quote{padding:32px 24px 28px 56px}\r\n}\r\n<\/style>\r\n\r\n<div class=\"midd-page\">\r\n\r\n  <!-- ================= HERO ================= -->\r\n  <header class=\"midd-hero\">\r\n    <div class=\"midd-wrap midd-hero-grid\">\r\n      <div>\r\n        <span class=\"midd-eyebrow\"><span class=\"dot\"><\/span>S\u00e9curit\u00e9 cardiaque<\/span>\r\n        <h1>R\u00e9duction du risque de <em>toxicit\u00e9 cardiaque<\/em><\/h1>\r\n        <p class=\"midd-sub\">L'\u00e9volution de l'\u00e9valuation de l'intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments<\/p>\r\n        <div class=\"midd-pills\">\r\n          <span class=\"midd-pill\">ICH E14<\/span>\r\n          <span class=\"midd-pill\">Canal hERG<\/span>\r\n          <span class=\"midd-pill\">CiPA<\/span>\r\n          <span class=\"midd-pill\">Mod\u00e9lisation C-QTc<\/span>\r\n        <\/div>\r\n      <\/div>\r\n      <div class=\"midd-img tall\" role=\"img\" aria-label=\"Illustration : suivi du rythme cardiaque sur montre connect\u00e9e\" style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png');\"><\/div>\r\n    <\/div>\r\n  <\/header>\r\n\r\n  <!-- ================= INTRO ================= -->\r\n  <section class=\"midd-section\" style=\"padding-top:0\">\r\n    <div class=\"midd-wrap midd-narrow\">\r\n      <p>Historiquement, la d\u00e9couverte d'un nouveau traitement \u00e9tait souvent compromise par un obstacle impr\u00e9vu et tardif : la toxicit\u00e9 cardiaque induite par les m\u00e9dicaments. Le retard involontaire de la repolarisation ventriculaire, mesur\u00e9 par l'allongement de l'intervalle QT, a \u00e9t\u00e9 l'une des principales causes de retrait de m\u00e9dicaments en raison de son association avec les torsades de pointes (TdP), une arythmie ventriculaire polymorphe potentiellement mortelle (Nachimuthu et al., 2012).<\/p>\r\n      <div class=\"midd-quote\">\r\n        <p>Il ne s'agit plus d'un goulot d'\u00e9tranglement en phase tardive, mais d'une science pr\u00e9dictive et m\u00e9thodique.<\/p>\r\n      <\/div>\r\n      <p>L'\u00e9valuation proactive de la s\u00e9curit\u00e9 cardiaque permet de maintenir dans le pipeline des m\u00e9dicaments par ailleurs efficaces, en identifiant et en att\u00e9nuant les risques d\u00e8s les premiers stades.<\/p>\r\n    <\/div>\r\n    <div class=\"midd-wrap\" style=\"margin-top:40px\">\r\n      <div class=\"midd-img banner\" role=\"img\" aria-label=\"Analyse ECG en laboratoire\" style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/phinc-labo-ecg-analysis-21-7.png');\"><\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"midd-divider\">\r\n\r\n  <!-- ================= 1. R\u00c9GLEMENTAIRE ================= -->\r\n  <section class=\"midd-section\">\r\n    <div class=\"midd-wrap midd-narrow\">\r\n      <span class=\"midd-kicker\">01 \u00b7 R\u00e9glementation<\/span>\r\n      <h2>Le changement de paradigme <em>r\u00e9glementaire<\/em><\/h2>\r\n      <div class=\"midd-compare\">\r\n        <div class=\"midd-compare-card\">\r\n          <p>Pendant des ann\u00e9es, l'\u00e9valuation de l'allongement de l'intervalle QT a \u00e9t\u00e9 fortement guid\u00e9e par le cadre r\u00e9glementaire <strong>ICH E14<\/strong>, qui a officiellement standardis\u00e9 la mani\u00e8re dont les promoteurs \u00e9valuent le potentiel proarythmique des traitements non antiarythmiques. Cette r\u00e9glementation historique a introduit l'obligation d'\u00e9valuer syst\u00e9matiquement le potentiel d'un m\u00e9dicament \u00e0 retarder la repolarisation cardiaque par le biais d'\u00e9tudes cliniques (Shah, 2005).<\/p>\r\n        <\/div>\r\n        <div class=\"midd-compare-card pink\">\r\n          <p>L'\u00e9tude traditionnelle de <strong>\u00ab Thorough QT \u00bb (TQT)<\/strong> n\u00e9cessite g\u00e9n\u00e9ralement que des volontaires sains re\u00e7oivent des doses th\u00e9rapeutiques et suprath\u00e9rapeutiques du m\u00e9dicament afin de mesurer rigoureusement son impact sur l'intervalle QT. Bien que tr\u00e8s sensible, l'\u00e9tude TQT traditionnelle n\u00e9cessite d'importantes ressources et signale souvent des compos\u00e9s qui allongent l'intervalle QT mais n'induisent pas r\u00e9ellement d'arythmies mortelles.<\/p>\r\n        <\/div>\r\n      <\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"midd-divider\">\r\n\r\n  <!-- ================= 2. M\u00c9CANISTE ================= -->\r\n  <section class=\"midd-section\">\r\n    <div class=\"midd-wrap\">\r\n      <div class=\"midd-narrow\">\r\n        <span class=\"midd-kicker\">02 \u00b7 M\u00e9canismes<\/span>\r\n        <h2>Compr\u00e9hension m\u00e9caniste : <em>le canal hERG et au-del\u00e0<\/em><\/h2>\r\n        <p>Au niveau cellulaire, le syndrome du QT long acquis est principalement provoqu\u00e9 par le blocage involontaire du canal potassique \u00e0 rectification retard\u00e9e rapide, connu sous le nom de canal hERG.<\/p>\r\n      <\/div>\r\n      <div class=\"midd-cards\">\r\n        <div class=\"midd-card\">\r\n          <div class=\"midd-chip\"><svg viewbox=\"0 0 24 24\"><path d=\"M3 12h4l2-5 4 10 2-5h6\"\/><\/svg><\/div>\r\n          <p>Lorsqu'un m\u00e9dicament inhibe le courant potassique rectifiant entrant, il augmente la dur\u00e9e du potentiel d'action, ce qui accro\u00eet le risque d'allongement de l'intervalle QT et de TdP (Nachimuthu et al., 2012).<\/p>\r\n        <\/div>\r\n        <div class=\"midd-card\">\r\n          <div class=\"midd-chip\"><svg viewbox=\"0 0 24 24\"><circle cx=\"6\" cy=\"12\" r=\"2.5\"\/><circle cx=\"18\" cy=\"6\" r=\"2.5\"\/><circle cx=\"18\" cy=\"18\" r=\"2.5\"\/><path d=\"M8.3 11l7.4-3.8M8.3 13l7.4 3.8\"\/><\/svg><\/div>\r\n          <p>Cependant, l'\u00e9valuation isol\u00e9e du canal hERG peut \u00eatre trompeuse, car certains m\u00e9dicaments poss\u00e8dent des effets multicanaux.<\/p>\r\n        <\/div>\r\n        <div class=\"midd-card\">\r\n          <div class=\"midd-chip\"><svg viewbox=\"0 0 24 24\"><path d=\"M7 3c0 6 10 6 10 12s-10 6-10 6M17 3c0 6-10 6-10 12\"\/><path d=\"M9 7h6M9 17h6\"\/><\/svg><\/div>\r\n          <p>En outre, une mutation dans les g\u00e8nes codant pour les canaux prot\u00e9iques ou un mauvais m\u00e9tabolisme des m\u00e9dicaments d\u00fb \u00e0 des polymorphismes de l'enzyme CYP2D6 peuvent augmenter la susceptibilit\u00e9 d'un patient aux TdP lors de l'exposition au m\u00e9dicament.<\/p>\r\n        <\/div>\r\n      <\/div>\r\n      <div class=\"midd-narrow\">\r\n        <p>Pour pallier les limites des \u00e9valuations traditionnelles, le domaine s'est tourn\u00e9 vers de nouvelles initiatives telles que le <em>Comprehensive in vitro Proarrhythmia Assay<\/em> (CiPA), s'\u00e9loignant d'une d\u00e9pendance exclusive au blocage isol\u00e9 de hERG et \u00e0 l'allongement du QTc comme substituts absolus du risque de TdP.<\/p>\r\n      <\/div>\r\n      <div class=\"midd-space\"><\/div>\r\n      <div class=\"midd-img\" role=\"img\" aria-label=\"Canal hERG et risque cardiaque\" style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/canal-herg-heart-attack-16-7.png');\"><\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"midd-divider\">\r\n\r\n  <!-- ================= 3. CAS D'USAGE ================= -->\r\n  <section class=\"midd-section\">\r\n    <div class=\"midd-wrap midd-narrow\">\r\n      <span class=\"midd-kicker\">03 \u00b7 Programmes cliniques<\/span>\r\n      <h2>Cas d'usage \u00e0 fort impact dans les <em>programmes cliniques<\/em><\/h2>\r\n      <p>\u00c0 l'instar de l'int\u00e9gration des m\u00e9thodologies de d\u00e9veloppement de m\u00e9dicaments bas\u00e9 sur la mod\u00e9lisation (MIDD) utilis\u00e9es pour d\u00e9finir la posologie et l'efficacit\u00e9 en oncologie, l'optimisation de la s\u00e9curit\u00e9 cardiaque repose sur des cadres quantitatifs rigoureux.<\/p>\r\n      <div class=\"midd-compare\">\r\n        <div class=\"midd-compare-card\">\r\n          <p><strong>Mod\u00e9lisation de la relation concentration-r\u00e9ponse :<\/strong> Au lieu de s'appuyer exclusivement sur une analyse d'\u00e9lectrocardiogramme (ECG) \u00e0 des moments pr\u00e9cis, les protocoles modernes utilisent la mod\u00e9lisation concentration-QTc (C-QTc). Celle-ci cartographie la relation exacte entre l'exposition au m\u00e9dicament (pharmacocin\u00e9tique) et l'allongement de l'intervalle QT (pharmacodynamique), ce qui permet souvent de s'affranchir d'une \u00e9tude TQT ind\u00e9pendante si les donn\u00e9es des premi\u00e8res phases d'administration chez l'homme (FIH, <em>First-in-Human<\/em>) sont robustes.<\/p>\r\n        <\/div>\r\n        <div class=\"midd-compare-card pink\">\r\n          <p><strong>Identification des sous-populations \u00e0 risque :<\/strong> \u00c9tant donn\u00e9 que certains patients pr\u00e9sentent une pr\u00e9disposition g\u00e9n\u00e9tique \u00e0 l'allongement du QT, la mod\u00e9lisation doit tenir compte de ces vuln\u00e9rabilit\u00e9s intrins\u00e8ques afin de pr\u00e9venir une toxicit\u00e9 inattendue en pratique clinique (Nachimuthu et al., 2012).<\/p>\r\n        <\/div>\r\n      <\/div>\r\n    <\/div>\r\n    <div class=\"midd-wrap\" style=\"margin-top:16px\">\r\n      <div class=\"midd-img\" role=\"img\" aria-label=\"Mod\u00e9lisation concentration-QTc\" style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/QTc-Analysis-Modeling.png');\"><\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"midd-divider\">\r\n\r\n  <!-- ================= 4. BONNES PRATIQUES ================= -->\r\n  <section class=\"midd-section\">\r\n    <div class=\"midd-wrap\">\r\n      <div class=\"midd-narrow\">\r\n        <span class=\"midd-kicker\">04 \u00b7 Recommandations<\/span>\r\n        <h2>Bonnes pratiques pour <em>les promoteurs<\/em><\/h2>\r\n        <p>Pour r\u00e9pondre avec succ\u00e8s aux attentes en mati\u00e8re de s\u00e9curit\u00e9 cardiaque, les d\u00e9veloppeurs de m\u00e9dicaments doivent adopter les strat\u00e9gies suivantes :<\/p>\r\n      <\/div>\r\n      <div class=\"midd-cards\">\r\n        <div class=\"midd-card\">\r\n          <div class=\"midd-chip\"><svg viewbox=\"0 0 24 24\"><path d=\"M9 3h6M10 3v6l-5 9a2 2 0 0 0 2 3h10a2 2 0 0 0 2-3l-5-9V3\"\/><path d=\"M7.5 14h9\"\/><\/svg><\/div>\r\n          <h3>Int\u00e9grer les donn\u00e9es <em>in vitro<\/em> et <em>in silico<\/em> \u00e0 un stade pr\u00e9coce :<\/h3>\r\n          <p>N'attendez pas la phase II ou III pour d\u00e9couvrir un risque proarythmique. Utilisez des tests de patch-clamp sur canaux multi-ioniques et des reconstructions <em>in silico<\/em> du potentiel d'action humain au cours des phases pr\u00e9cliniques.<\/p>\r\n          <div class=\"midd-tags\"><span class=\"midd-tag\">Pr\u00e9clinique<\/span><span class=\"midd-tag\">Patch-clamp<\/span><\/div>\r\n        <\/div>\r\n        <div class=\"midd-card\">\r\n          <div class=\"midd-chip\"><svg viewbox=\"0 0 24 24\"><rect x=\"3\" y=\"4\" width=\"18\" height=\"14\" rx=\"2\"\/><path d=\"M5 12h3l1.5-3 2.5 6 1.5-3H19\"\/><path d=\"M8 21h8\"\/><\/svg><\/div>\r\n          <h3>Tirer parti du monitorage ECG intensif en phase I :<\/h3>\r\n          <p>Int\u00e9grez une extraction continue et de haute qualit\u00e9 de l'ECG dans les \u00e9tudes \u00e0 dose unique ou \u00e0 doses multiples croissantes. Des donn\u00e9es pr\u00e9coces robustes, associ\u00e9es \u00e0 une mod\u00e9lisation concentration-r\u00e9ponse, permettent de satisfaire aux exigences r\u00e9glementaires beaucoup plus t\u00f4t dans le cycle de d\u00e9veloppement.<\/p>\r\n          <div class=\"midd-tags\"><span class=\"midd-tag\">Phase I<\/span><span class=\"midd-tag\">C-QTc<\/span><\/div>\r\n        <\/div>\r\n        <div class=\"midd-card\">\r\n          <div class=\"midd-chip\"><svg viewbox=\"0 0 24 24\"><rect x=\"3\" y=\"9\" width=\"10\" height=\"6\" rx=\"3\" transform=\"rotate(-35 8 12)\"\/><rect x=\"11\" y=\"9\" width=\"10\" height=\"6\" rx=\"3\" transform=\"rotate(35 16 12)\"\/><\/svg><\/div>\r\n          <h3>\u00c9valuer les interactions m\u00e9dicamenteuses (IAM) :<\/h3>\r\n          <p>Les patients sont fr\u00e9quemment confront\u00e9s \u00e0 la polypharmacie. Les promoteurs doivent \u00e9valuer rigoureusement la mani\u00e8re dont les traitements concomitants modifient la pharmacocin\u00e9tique de leur m\u00e9dicament. Tout comme la mod\u00e9lisation des interactions est vitale pour pr\u00e9server l'observance des essais en oncologie et att\u00e9nuer les risques en vie r\u00e9elle, l'identification des IAM cardiovasculaires dangereuses garantit la s\u00e9curit\u00e9 des patients en pratique courante.<\/p>\r\n          <div class=\"midd-tags\"><span class=\"midd-tag\">Polypharmacie<\/span><span class=\"midd-tag\">PK<\/span><\/div>\r\n        <\/div>\r\n      <\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"midd-divider\">\r\n\r\n  <!-- ================= CONCLUSION ================= -->\r\n  <section class=\"midd-section\">\r\n    <div class=\"midd-wrap midd-narrow\">\r\n     \r\n      <p>\u00c0 mesure que les modalit\u00e9s th\u00e9rapeutiques se complexifient, la garantie de la s\u00e9curit\u00e9 cardiovasculaire reste une priorit\u00e9 absolue. En allant au-del\u00e0 des simples essais de blocage de hERG et des approches traditionnelles gourmandes en ressources, les promoteurs peuvent mettre en \u0153uvre des pr\u00e9dictions du risque proarythmique plus pr\u00e9cises et bas\u00e9es sur les m\u00e9canismes.<\/p>\r\n      <div class=\"midd-quote\">\r\n        <p>L'adoption de la mod\u00e9lisation C-QTc int\u00e9gr\u00e9e et d'essais pr\u00e9cliniques proactifs transforme la s\u00e9curit\u00e9 cardiaque, faisant de cet obstacle impr\u00e9visible un atout scientifique rationalis\u00e9.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"midd-divider\">\r\n\r\n  <!-- ================= R\u00c9F\u00c9RENCES ================= -->\r\n  <section class=\"midd-section midd-refs\">\r\n    <div class=\"midd-wrap midd-narrow\">\r\n      <span class=\"midd-kicker\">Sources<\/span>\r\n      <h2><em>R\u00e9f\u00e9rences<\/em><\/h2>\r\n      <p>Nachimuthu, S., Assar, M. D., &amp; Schussler, J. M. (2012). Drug-induced QT interval prolongation: mechanisms and clinical management. <em>Therapeutic Advances in Drug Safety<\/em>, 3, 241\u2013253. <a href=\"https:\/\/doi.org\/10.1177\/2042098612454283\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1177\/2042098612454283<\/a><\/p>\r\n      <p>Shah, R. R. (2005). Drugs, QTc Interval Prolongation and Final ICH E14 Guideline. <em>Drug Safety<\/em>, 28, 1009\u20131028. <a href=\"https:\/\/doi.org\/10.2165\/00002018-200528110-00003\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.2165\/00002018-200528110-00003<\/a><\/p>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <!-- ================= CTA ================= -->\r\n  <div class=\"midd-wrap\">\r\n    <div class=\"midd-cta\">\r\n      <h2>S\u00e9curisez votre programme <em>d\u00e8s les premi\u00e8res phases<\/em><\/h2>\r\n      <p>Nos experts en pharmacom\u00e9trie et MIDD vous accompagnent dans l'\u00e9valuation du risque cardiaque, de la mod\u00e9lisation C-QTc \u00e0 la strat\u00e9gie r\u00e9glementaire.<\/p>\r\n      <div class=\"midd-btns\">\r\n        <a class=\"midd-btn primary\" href=\"\/fr\/contact\/\">Contactez nos experts<\/a>\r\n        <a class=\"midd-btn ghost\" href=\"\/fr\/midd\/\">D\u00e9couvrir le MIDD<\/a>\r\n      <\/div>\r\n    <\/div>\r\n  <\/div>\r\n\r\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>",
        "protected": false
    },
    "excerpt": {
        "rendered": "<p>La d\u00e9couverte d&rsquo;un nouveau traitement \u00e9tait souvent compromise par un obstacle impr\u00e9vu et tardif : la toxicit\u00e9 cardiaque induite par les m\u00e9dicaments. Le retard involontaire de la repolarisation ventriculaire, mesur\u00e9 par l&rsquo;allongement de l&rsquo;intervalle QT, a \u00e9t\u00e9 l&rsquo;une des principales causes de retrait de m\u00e9dicaments.<\/p>",
        "protected": false
    },
    "author": 2,
    "featured_media": 5179,
    "comment_status": "closed",
    "ping_status": "closed",
    "sticky": false,
    "template": "elementor_header_footer",
    "format": "standard",
    "meta": {
        "_acf_changed": false,
        "footnotes": ""
    },
    "categories": [
        39,
        37
    ],
    "tags": [],
    "service-associe": [],
    "class_list": [
        "post-5183",
        "post",
        "type-post",
        "status-publish",
        "format-standard",
        "has-post-thumbnail",
        "hentry",
        "category-a-la-une",
        "category-blog"
    ],
    "acf": [],
    "yoast_head": "<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>R\u00e9duction du risque de toxicit\u00e9 cardiaque : L&#039;\u00e9volution de l&#039;\u00e9valuation de l&#039;intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/fr\/reduction-du-risque-de-toxicite-cardiaque\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9duction du risque de toxicit\u00e9 cardiaque : L&#039;\u00e9volution de l&#039;\u00e9valuation de l&#039;intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"La d\u00e9couverte d&#039;un nouveau traitement \u00e9tait souvent compromise par un obstacle impr\u00e9vu et tardif : la toxicit\u00e9 cardiaque induite par les m\u00e9dicaments. Le retard involontaire de la repolarisation ventriculaire, mesur\u00e9 par l&#039;allongement de l&#039;intervalle QT, a \u00e9t\u00e9 l&#039;une des principales causes de retrait de m\u00e9dicaments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/fr\/reduction-du-risque-de-toxicite-cardiaque\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-24T09:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T10:47:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1448\" \/>\n\t<meta property=\"og:image:height\" content=\"1086\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"R\u00e9duction du risque de toxicit\u00e9 cardiaque : L&rsquo;\u00e9volution de l&rsquo;\u00e9valuation de l&rsquo;intervalle QT\\\/QTc dans le d\u00e9veloppement de m\u00e9dicaments\",\"datePublished\":\"2026-09-24T09:55:00+00:00\",\"dateModified\":\"2026-09-24T10:47:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/\"},\"wordCount\":1126,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Cardiac-safety-hero-image-4-3.png\",\"articleSection\":[\"A la une\",\"Blog\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/\",\"name\":\"R\u00e9duction du risque de toxicit\u00e9 cardiaque : L'\u00e9volution de l'\u00e9valuation de l'intervalle QT\\\/QTc dans le d\u00e9veloppement de m\u00e9dicaments - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Cardiac-safety-hero-image-4-3.png\",\"datePublished\":\"2026-09-24T09:55:00+00:00\",\"dateModified\":\"2026-09-24T10:47:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Cardiac-safety-hero-image-4-3.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Cardiac-safety-hero-image-4-3.png\",\"width\":1448,\"height\":1086},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/reduction-du-risque-de-toxicite-cardiaque\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R\u00e9duction du risque de toxicit\u00e9 cardiaque : L&rsquo;\u00e9volution de l&rsquo;\u00e9valuation de l&rsquo;intervalle QT\\\/QTc dans le d\u00e9veloppement de m\u00e9dicaments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions &amp; Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->",
    "yoast_head_json": {
        "title": "R\u00e9duction du risque de toxicit\u00e9 cardiaque : L'\u00e9volution de l'\u00e9valuation de l'intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments - PhinC Group",
        "robots": {
            "index": "index",
            "follow": "follow",
            "max-snippet": "max-snippet:-1",
            "max-image-preview": "max-image-preview:large",
            "max-video-preview": "max-video-preview:-1"
        },
        "canonical": "https:\/\/www.phinc-group.com\/fr\/reduction-du-risque-de-toxicite-cardiaque\/",
        "og_locale": "fr_FR",
        "og_type": "article",
        "og_title": "R\u00e9duction du risque de toxicit\u00e9 cardiaque : L'\u00e9volution de l'\u00e9valuation de l'intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments - PhinC Group",
        "og_description": "La d\u00e9couverte d'un nouveau traitement \u00e9tait souvent compromise par un obstacle impr\u00e9vu et tardif : la toxicit\u00e9 cardiaque induite par les m\u00e9dicaments. Le retard involontaire de la repolarisation ventriculaire, mesur\u00e9 par l'allongement de l'intervalle QT, a \u00e9t\u00e9 l'une des principales causes de retrait de m\u00e9dicaments.",
        "og_url": "https:\/\/www.phinc-group.com\/fr\/reduction-du-risque-de-toxicite-cardiaque\/",
        "og_site_name": "PhinC Group",
        "article_published_time": "2026-09-24T09:55:00+00:00",
        "article_modified_time": "2026-09-24T10:47:04+00:00",
        "og_image": [
            {
                "width": 1448,
                "height": 1086,
                "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png",
                "type": "image\/png"
            }
        ],
        "author": "Mohamed Taourirt",
        "twitter_card": "summary_large_image",
        "twitter_misc": {
            "\u00c9crit par": "Mohamed Taourirt",
            "Dur\u00e9e de lecture estim\u00e9e": "5 minutes"
        },
        "schema": {
            "@context": "https:\/\/schema.org",
            "@graph": [
                {
                    "@type": "Article",
                    "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#article",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/"
                    },
                    "author": {
                        "name": "Mohamed Taourirt",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"
                    },
                    "headline": "R\u00e9duction du risque de toxicit\u00e9 cardiaque : L&rsquo;\u00e9volution de l&rsquo;\u00e9valuation de l&rsquo;intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments",
                    "datePublished": "2026-09-24T09:55:00+00:00",
                    "dateModified": "2026-09-24T10:47:04+00:00",
                    "mainEntityOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/"
                    },
                    "wordCount": 1126,
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png",
                    "articleSection": [
                        "A la une",
                        "Blog"
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "WebPage",
                    "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/",
                    "url": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/",
                    "name": "R\u00e9duction du risque de toxicit\u00e9 cardiaque : L'\u00e9volution de l'\u00e9valuation de l'intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments - PhinC Group",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#website"
                    },
                    "primaryImageOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#primaryimage"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png",
                    "datePublished": "2026-09-24T09:55:00+00:00",
                    "dateModified": "2026-09-24T10:47:04+00:00",
                    "breadcrumb": {
                        "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#breadcrumb"
                    },
                    "inLanguage": "fr-FR",
                    "potentialAction": [
                        {
                            "@type": "ReadAction",
                            "target": [
                                "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/"
                            ]
                        }
                    ]
                },
                {
                    "@type": "ImageObject",
                    "inLanguage": "fr-FR",
                    "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#primaryimage",
                    "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png",
                    "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/09\/Cardiac-safety-hero-image-4-3.png",
                    "width": 1448,
                    "height": 1086
                },
                {
                    "@type": "BreadcrumbList",
                    "@id": "https:\/\/www.phinc-group.com\/reduction-du-risque-de-toxicite-cardiaque\/#breadcrumb",
                    "itemListElement": [
                        {
                            "@type": "ListItem",
                            "position": 1,
                            "name": "Accueil",
                            "item": "https:\/\/www.phinc-group.com\/en\/"
                        },
                        {
                            "@type": "ListItem",
                            "position": 2,
                            "name": "R\u00e9duction du risque de toxicit\u00e9 cardiaque : L&rsquo;\u00e9volution de l&rsquo;\u00e9valuation de l&rsquo;intervalle QT\/QTc dans le d\u00e9veloppement de m\u00e9dicaments"
                        }
                    ]
                },
                {
                    "@type": "WebSite",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#website",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "name": "PhinC Group",
                    "description": "Quantitative Pharmacology Solutions &amp; Modeling",
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "potentialAction": [
                        {
                            "@type": "SearchAction",
                            "target": {
                                "@type": "EntryPoint",
                                "urlTemplate": "https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"
                            },
                            "query-input": {
                                "@type": "PropertyValueSpecification",
                                "valueRequired": true,
                                "valueName": "search_term_string"
                            }
                        }
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "Organization",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#organization",
                    "name": "PhinC Group",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "logo": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/",
                        "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "width": 600,
                        "height": 600,
                        "caption": "PhinC Group"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"
                    }
                },
                {
                    "@type": "Person",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a",
                    "name": "Mohamed Taourirt",
                    "image": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "url": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "contentUrl": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "caption": "Mohamed Taourirt"
                    },
                    "url": "https:\/\/www.phinc-group.com\/fr\/author\/mtaourirt\/"
                }
            ]
        }
    },
    "_links": {
        "self": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5183",
                "targetHints": {
                    "allow": [
                        "GET"
                    ]
                }
            }
        ],
        "collection": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts"
            }
        ],
        "about": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/types\/post"
            }
        ],
        "author": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/users\/2"
            }
        ],
        "replies": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/comments?post=5183"
            }
        ],
        "version-history": [
            {
                "count": 5,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5183\/revisions"
            }
        ],
        "predecessor-version": [
            {
                "id": 5191,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5183\/revisions\/5191"
            }
        ],
        "wp:featuredmedia": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media\/5179"
            }
        ],
        "wp:attachment": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media?parent=5183"
            }
        ],
        "wp:term": [
            {
                "taxonomy": "category",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/categories?post=5183"
            },
            {
                "taxonomy": "post_tag",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/tags?post=5183"
            },
            {
                "taxonomy": "service-associe",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/service-associe?post=5183"
            }
        ],
        "curies": [
            {
                "name": "wp",
                "href": "https:\/\/api.w.org\/{rel}",
                "templated": true
            }
        ]
    }
}